Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

597 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer.
Bertucci F, Borie N, Roche H, Bachelot T, Le Doussal JM, Macgrogan G, Debono S, Martinec A, Treilleux I, Finetti P, Esterni B, Extra JM, Geneve J, Hermitte F, Chabannon C, Jacquemier J, Martin AL, Longy M, Maraninchi D, Fert V, Birnbaum D, Viens P. Bertucci F, et al. Among authors: roche h. Breast Cancer Res Treat. 2011 Jun;127(2):363-73. doi: 10.1007/s10549-010-1003-z. Epub 2010 Jun 29. Breast Cancer Res Treat. 2011. PMID: 20585850
A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
Jézéquel P, Campone M, Roché H, Gouraud W, Charbonnel C, Ricolleau G, Magrangeas F, Minvielle S, Genève J, Martin AL, Bataille R, Campion L. Jézéquel P, et al. Among authors: roche h. Breast Cancer Res Treat. 2009 Aug;116(3):509-20. doi: 10.1007/s10549-008-0250-8. Epub 2008 Nov 20. Breast Cancer Res Treat. 2009. PMID: 19020972
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial.
Jacquemier J, Boher JM, Roche H, Esterni B, Serin D, Kerbrat P, Andre F, Finetti P, Charafe-Jauffret E, Martin AL, Campone M, Viens P, Birnbaum D, Penault-Llorca F, Bertucci F. Jacquemier J, et al. Among authors: roche h. Breast Cancer Res. 2011;13(6):R109. doi: 10.1186/bcr3051. Epub 2011 Nov 1. Breast Cancer Res. 2011. PMID: 22044691 Free PMC article. Clinical Trial.
Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer.
Sabatier R, Diéras V, Pivot X, Brain E, Roché H, Extra JM, Monneur A, Provansal M, Tarpin C, Bertucci F, Viens P, Zemmour C, Gonçalves A. Sabatier R, et al. Among authors: roche h. Cancer Res Treat. 2018 Oct;50(4):1226-1237. doi: 10.4143/crt.2017.446. Epub 2017 Dec 28. Cancer Res Treat. 2018. PMID: 29281873 Free PMC article.
MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.
Tabouret E, Bertucci F, Pierga JY, Petit T, Levy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, van Laere S, Ueno NT, Toiron Y, Finetti P, Birnbaum D, Borg JP, Viens P, Chinot O, Gonçalves A. Tabouret E, et al. Among authors: roche h. Oncotarget. 2016 Apr 5;7(14):18531-40. doi: 10.18632/oncotarget.7612. Oncotarget. 2016. PMID: 26921265 Free PMC article. Clinical Trial.
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulié P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Genève J, Asselain B. Roché H, et al. J Clin Oncol. 2006 Dec 20;24(36):5664-71. doi: 10.1200/JCO.2006.07.3916. Epub 2006 Nov 20. J Clin Oncol. 2006. PMID: 17116941 Clinical Trial.
Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data.
Pierga JY, Petit T, Lévy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, Charafe-Jauffret E, Bonneterre J, Hernandez J, Bidard FC, Viens P. Pierga JY, et al. Among authors: roche h. Clin Cancer Res. 2015 Mar 15;21(6):1298-304. doi: 10.1158/1078-0432.CCR-14-1705. Epub 2014 Dec 23. Clin Cancer Res. 2015. PMID: 25538259 Clinical Trial.
Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).
Kerbrat P, Desmoulins I, Roca L, Levy C, Lortholary A, Marre A, Delva R, Rios M, Viens P, Brain É, Serin D, Edel M, Debled M, Campone M, Mourret-Reynier MA, Bachelot T, Foucher-Goudier MJ, Asselain B, Lemonnier J, Martin AL, Roché H. Kerbrat P, et al. Among authors: roche h. Eur J Cancer. 2017 Jul;79:166-175. doi: 10.1016/j.ejca.2017.03.004. Epub 2017 May 11. Eur J Cancer. 2017. PMID: 28501763 Clinical Trial.
597 results